Reduction of cardiovascular disease in type 2 diabetes

Sept. 14, 2012 - PRLog -- The number of diabetics is growing at an alarming rate and the World Health Organisation (WHO) forecast that eight percent of the world’s adult population, around 400 million people, will be affected by 2030.  This has led the World Health Organization to describe diabetes as a global epidemic.  

SMi is pleased to confirm Phil Ambery, Medical director, Cardiovascualr and Metabolic R&D from GlaxoSmithKline as speaker at the upcoming event.

He will address the links between diabetes and CVD, Novel diabetes drugs and CVD and future directions. Join your peers at the only conference dedicated to this topic this autumn, as the unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Attending will enable you to:

Receive updates on novel GLP-1 receptor agonists, SGLT2 and DPP-4 inhibitors

Review clinical results from the DEMAND study

Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies

Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation

Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments

Register today to hear about the current development in novel GLP1 receptor agonists from top pharma companies and academics. For further information and to register visit http://www.smi-online.co.uk/diabetes-conference54.asp or contact Farhaana Rahman on tel +44 0 207 827 6186 or email frahman@smi-online.co.uk